LLY · Company research
Eli Lilly & Co. (LLY): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
80records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth | GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0.111 | 1 |
| Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts | Eli Lilly (LLY) closed at $1,240.34, down 1.33% in the latest session. The pharmaceutical giant holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 37.46, significantly above its industry average of 16.91. While the company is expected to report 25.59% revenue growth for the upcoming quarter, EPS is anticipated to decline 23.36% year-over-year. The Large Cap Pharmaceuticals industry ranks in the bottom 15% of all industries. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | neutral | 0 | 1 |
| Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight | The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Is Eli Lilly Stock a Buy Right Now? | Eli Lilly is expanding access to its products at lower realized prices while improving margins—an unusual combination that could strengthen further as manufacturing costs decline. The company's retatrutide drug approaches a potential 2027 filing, and investors are evaluating whether the current valuation still offers room for growth. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 1 | 1 |
| Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market | Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 0.333 | 1 |
| Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch | Pfizer will report Q3 2026 earnings on November 3, with focus on non-oncology segments. Eliquis demand is expected to boost Primary Care sales, while COVID-19 vaccine and Paxlovid revenues will decline. Specialty Care segment may see Vyndaqel growth offset by declines in Xeljanz and Enbrel due to competitive pressures. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.167 | 1 |
| How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? | Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, up 88% year-over-year, accounting for 65% of total revenues. The company's newly launched oral obesity therapy Foundayo posted $98 million in Q2 sales with expanding coverage. Lilly faces competition from Novo Nordisk's semaglutide drugs and emerging biotech firms developing alternative GLP-1 therapies. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.25 | 1 |
| Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It | Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 0.6 | 1 |
| Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. | Viking Therapeutics raised $575 million through a stock offering and convertible notes to fund multiple phase 3 trials for its obesity drug VK2735 and pipeline development. The company expects to have cash through at least 2028, with key trial results expected between 2027-2028. The company's future depends on VK2735's clinical success. | View source ↗ | The Motley Fool | Oct 18, 2026 | bullish | 0.333 | 1 |
| Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher | Eli Lilly's pipeline extends beyond its blockbuster weight-loss drug Zepbound, with three promising medicines poised to drive future growth: Foundayo (oral GLP-1 for weight loss), Onswik (once-weekly basal insulin for diabetes), and retatrutide (investigational triple-hormone weight-loss drug showing 28.3% average weight loss). These drugs target different patient segments and indications, positioning Eli Lilly to maintain market leadership despite increasing competition. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Novo Nordisk and Eli Lilly Just Got Some Fantastic News | A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| Novo Nordisk and Eli Lilly Just Got Some Fantastic News | A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| Stock Market News for Oct 16, 2026 | Wall Street rallied on Thursday with all three major indexes closing in the green, driven by a rotation into defensive sectors like healthcare, materials, and financials. Investors shifted away from debt-sensitive AI and technology stocks as Treasury yields fell. The Dow Jones jumped 1.1%, the S&P 500 added 0.3%, and the Nasdaq gained 0.1%, while economic data showed mixed signals with jobless claims rising slightly and PPI inflation at 1.3%. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.667 | 1 |
| Stock Market News for Oct 16, 2026 | Wall Street rallied on Thursday with all three major indexes closing in the green, driven by a rotation into defensive sectors like healthcare, materials, and financials. Investors shifted away from debt-sensitive AI and technology stocks as Treasury yields fell. The Dow Jones jumped 1.1%, the S&P 500 added 0.3%, and the Nasdaq gained 0.1%, while economic data showed mixed signals with jobless claims rising slightly and PPI inflation at 1.3%. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.667 | 1 |
| Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? | The Lilly Foundation, Eli Lilly's largest shareholder with 9.6% ownership, is selling 300,000 shares worth $347 million. However, this sale is a required annual charity payout and does not reflect bearish sentiment on the stock. Eli Lilly is leading the GLP-1 drug revolution with its tirzepatide drug (Mounjaro/Zepbound) becoming the world's best-selling drug. With Morgan Stanley forecasting the GLP-1 market to reach $190 billion by 2035 and Wall Street analysts targeting 10% upside, the article recommends buying rather than selling. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? | The Lilly Foundation, Eli Lilly's largest shareholder with 9.6% ownership, is selling 300,000 shares worth $347 million. However, this sale is a required annual charity payout and does not reflect bearish sentiment on the stock. Eli Lilly is leading the GLP-1 drug revolution with its tirzepatide drug (Mounjaro/Zepbound) becoming the world's best-selling drug. With Morgan Stanley forecasting the GLP-1 market to reach $190 billion by 2035 and Wall Street analysts targeting 10% upside, the article recommends buying rather than selling. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Viking Therapeutics Starts Phase III Development of Obesity Pill | Viking Therapeutics announced the initiation of the SUNRISE phase III program to evaluate its oral VK2735 formulation for obesity treatment. The program consists of two studies targeting 560 adults each, with and without type 2 diabetes. Phase II results showed up to 12.2% mean weight loss at the highest dose versus 1.3% with placebo. Despite positive developments, VKTX stock declined 4.4% on the announcement day and is down 27.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.333 | 1 |
| Viking Therapeutics Starts Phase III Development of Obesity Pill | Viking Therapeutics announced the initiation of the SUNRISE phase III program to evaluate its oral VK2735 formulation for obesity treatment. The program consists of two studies targeting 560 adults each, with and without type 2 diabetes. Phase II results showed up to 12.2% mean weight loss at the highest dose versus 1.3% with placebo. Despite positive developments, VKTX stock declined 4.4% on the announcement day and is down 27.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.333 | 1 |
| Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? | Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? | Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years - Benzinga | Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| Eli Lilly and Co Stock (LLY) Opened Up by 3.50% on Oct 15: Drivers Behind the Movement - TradingKey | Eli Lilly and Co Stock (LLY) Opened Up by 3.50% on Oct 15: Drivers Behind the Movement TradingKey | View source ↗ | TradingKey | Oct 15, 2026 | neutral | 0 | 0.6 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| 5 Stocks to Start With if You Only Have $1,000 | The article recommends five diversified stocks for beginner investors with $1,000: Palantir Technologies for growth through AI, AGNC for high dividend income, Eli Lilly for healthcare exposure, SoFi for fintech innovation, and Berkshire Hathaway for stability and security. The piece emphasizes that even small initial investments can compound significantly over decades, with potential returns ranging from $2,594 to $267,864 depending on annual growth rates. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 1 | 1 |
| 5 Stocks to Start With if You Only Have $1,000 | The article recommends five diversified stocks for beginner investors with $1,000: Palantir Technologies for growth through AI, AGNC for high dividend income, Eli Lilly for healthcare exposure, SoFi for fintech innovation, and Berkshire Hathaway for stability and security. The piece emphasizes that even small initial investments can compound significantly over decades, with potential returns ranging from $2,594 to $267,864 depending on annual growth rates. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 1 | 1 |
| Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? | The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? | The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| LLY Stock Analysis: Explained - JournalArta | LLY Stock Analysis: Explained JournalArta | View source ↗ | JournalArta | Oct 15, 2026 | neutral | 0 | 0.6 |
| Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day - TIKR.com | Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day TIKR.com | View source ↗ | TIKR.com | Oct 15, 2026 | neutral | 0 | 0.6 |
| Eli Lilly (NYSE:LLY) Stock Surges Nearly 4% as Investors Rotate Out of Tech - Stocks Down Under | Eli Lilly (NYSE:LLY) Stock Surges Nearly 4% as Investors Rotate Out of Tech Stocks Down Under | View source ↗ | Stocks Down Under | Oct 14, 2026 | neutral | 0 | 0.6 |
| Eli Lilly (LLY) Stock Looks Undervalued As Its 404% Run Continues - Yahoo Finance | Eli Lilly (LLY) Stock Looks Undervalued As Its 404% Run Continues Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Eli Lilly Rallies as Investors Revisit Obesity Pipeline and Bullish Price Targets - Quiver Quantitative | Eli Lilly Rallies as Investors Revisit Obesity Pipeline and Bullish Price Targets Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 14, 2026 | neutral | 0 | 0.6 |
| Roche Expands Obesity Pipeline With Rona's RNAi Candidate | Roche has secured worldwide rights to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity treatment, with up to $100 million upfront and $1.06 billion in potential milestone payments. The deal strengthens Roche's metabolic disease pipeline alongside its Phase III enicepatide program, though the company faces intense competition from Eli Lilly and Novo Nordisk in the rapidly growing obesity market. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.75 | 1 |
| LLY Stock Powers Higher As Obesity And Diabetes Pipeline Deepens - StocksToTrade | LLY Stock Powers Higher As Obesity And Diabetes Pipeline Deepens StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% | Major stock indexes declined on October 14, 2026, as a hotter-than-expected CPI report of 3.7% revived concerns about potential Federal Reserve rate hikes. The S&P 500 fell 0.91%, the Nasdaq dropped 1.31%, and the Dow slipped 0.09%. The semiconductor sector led declines with a 10% drop over five days, while Bank of America fell 6% following a $1.2 billion regulatory fine. CoreWeave plummeted 15% due to rising bond yields, and GlobalFoundries surged after securing a major U.S.-Japan semiconductor initiative with up to $21 billion in funding. | View source ↗ | The Motley Fool | Oct 14, 2026 | bearish | -0.762 | 1 |
| Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% | Major stock indexes declined on October 14, 2026, as a hotter-than-expected CPI report of 3.7% revived concerns about potential Federal Reserve rate hikes. The S&P 500 fell 0.91%, the Nasdaq dropped 1.31%, and the Dow slipped 0.09%. The semiconductor sector led declines with a 10% drop over five days, while Bank of America fell 6% following a $1.2 billion regulatory fine. CoreWeave plummeted 15% due to rising bond yields, and GlobalFoundries surged after securing a major U.S.-Japan semiconductor initiative with up to $21 billion in funding. | View source ↗ | The Motley Fool | Oct 14, 2026 | bearish | -0.762 | 1 |
| Why is Eli Lilly stock rallying today? - Investing.com | Why is Eli Lilly stock rallying today? Investing.com | View source ↗ | Investing.com | Oct 14, 2026 | neutral | 0 | 0.6 |
| 4 High-Risk Stocks Built for Big Returns | The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 0.571 | 1 |
| 4 High-Risk Stocks Built for Big Returns | The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 0.571 | 1 |
| Here's Why Eli Lilly (LLY) Fell More Than Broader Market | Eli Lilly (LLY) closed down 1.04% to $1,170.34, underperforming the broader market. The pharmaceutical company is expected to report Q3 2026 earnings on October 29 with projected EPS of $7.54 (+7.41% YoY) and revenue of $22.11 billion (+25.59% YoY). However, the Zacks Consensus EPS estimate has fallen 4.77% over the past month, and the stock carries a Hold rating (Zacks Rank #3) with a premium valuation at 33.99 Forward P/E versus the industry average of 16.15. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| 3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years | Eli Lilly, Tractor Supply Company, and American Express have each doubled their dividend payouts over the past five years. Despite varying yields and current market challenges, all three stocks maintain modest payout ratios, suggesting room for continued dividend growth. These companies represent attractive long-term investments for dividend-focused investors seeking both income and capital appreciation. | View source ↗ | The Motley Fool | Oct 13, 2026 | bullish | 1 | 1 |
| 3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years | Eli Lilly, Tractor Supply Company, and American Express have each doubled their dividend payouts over the past five years. Despite varying yields and current market challenges, all three stocks maintain modest payout ratios, suggesting room for continued dividend growth. These companies represent attractive long-term investments for dividend-focused investors seeking both income and capital appreciation. | View source ↗ | The Motley Fool | Oct 13, 2026 | bullish | 1 | 1 |
| What Is Eli Lilly Stock’s Biggest Opportunity? - Trefis | What Is Eli Lilly Stock’s Biggest Opportunity? Trefis | View source ↗ | Trefis | Oct 13, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff - 24/7 Wall St. | Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 13, 2026 | neutral | 0 | 0.6 |
| BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail | BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY) The Globe and Mail | View source ↗ | The Globe and Mail | Oct 13, 2026 | neutral | 0 | 0.6 |
| Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? | The Invesco Dividend Achievers ETF (PFM) is a passively managed large-cap value fund with $788.33 million in assets and a 0.52% expense ratio. It tracks companies with 10+ consecutive years of dividend increases, delivering 10.66% YTD returns and 14.39% one-year returns. With a Zacks ETF Rank of 3 (Hold), it offers medium risk diversification but faces competition from lower-cost alternatives like SCHD (0.06%) and VTV (0.03%). | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? | The Invesco Dividend Achievers ETF (PFM) is a passively managed large-cap value fund with $788.33 million in assets and a 0.52% expense ratio. It tracks companies with 10+ consecutive years of dividend increases, delivering 10.66% YTD returns and 14.39% one-year returns. With a Zacks ETF Rank of 3 (Hold), it offers medium risk diversification but faces competition from lower-cost alternatives like SCHD (0.06%) and VTV (0.03%). | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. | Eli Lilly's weight loss drug portfolio, led by Mounjaro and Zepbound, is driving explosive revenue growth with expectations of up to $87 billion in 2026 revenue compared to $65 billion in 2025. Despite a 400% gain over five years and 25% rise in the past six months, the stock trades at 32x forward earnings—below historical levels—and appears undervalued given strong pipeline candidates like EloraTZP and retatrutide that could further expand the company's weight loss drug offerings. | View source ↗ | The Motley Fool | Oct 13, 2026 | bullish | 0.5 | 1 |
| Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. | Eli Lilly's weight loss drug portfolio, led by Mounjaro and Zepbound, is driving explosive revenue growth with expectations of up to $87 billion in 2026 revenue compared to $65 billion in 2025. Despite a 400% gain over five years and 25% rise in the past six months, the stock trades at 32x forward earnings—below historical levels—and appears undervalued given strong pipeline candidates like EloraTZP and retatrutide that could further expand the company's weight loss drug offerings. | View source ↗ | The Motley Fool | Oct 13, 2026 | bullish | 0.5 | 1 |
| Novo Down 11% in a Month: How Should Investors Approach the Stock Now? | Novo Nordisk shares fell 11.1% over the past month following disappointing Capital Markets Day guidance that lacked near-term clarity. The company faces headwinds from intensifying competition with Eli Lilly's obesity drugs, lower U.S. pricing pressure, and pipeline setbacks including the failed CagriSema trial. While long-term opportunities exist in rare diseases and next-generation GLP-1 candidates, short-term investors should wait for stabilization signs, though long-term holders may maintain positions given valuation discounts and market potential. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.5 | 1 |
| 4 Healthcare Stocks Worth Owning for the Next Decade | The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 0.75 | 1 |
| Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? | Pfizer's stock has moved above its 50-day moving average, supported by new drug launches and acquisitions. While the company faces significant headwinds from declining COVID-19 product sales and an upcoming patent cliff, its diversified portfolio, strong oncology pipeline, obesity drug berobenatide program, attractive 6.1% dividend yield, and $9.7 billion in cost savings through 2029 provide support. Analysts recommend holding the stock at current levels given its inexpensive valuation relative to peers. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.667 | 1 |
| Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. | Oppenheimer analyst Jay Olson raised his price target on Viking Therapeutics to $120 from $100, implying a potential quadrupling from the current $28.50 price. The bullish call is based on positive maintenance trial data for VK2735, a GLP-1 and GIP agonist drug, which increased the probability of success from 80% to 90%. Wall Street consensus projects VK2735 could generate $1.5 billion in 2030 sales rising to $6.5 billion by 2035, potentially capturing market share from Eli Lilly's tirzepatide, which is expected to reach $80 billion in total sales by 2030. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 0.5 | 1 |
| Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? | Viking Therapeutics is advancing its oral weight-loss drug VK2735 to Phase 3 trials, showing 12.2% weight loss in Phase 2 testing. However, the company faces significant competitive challenges from established players like Eli Lilly's Foundayo, which demonstrated better tolerability with lower discontinuation rates. While Viking's injectable formulation shows promise with potential monthly dosing differentiation, the biotech will struggle to gain market traction in an increasingly crowded obesity drug market dominated by incumbents. | View source ↗ | The Motley Fool | Oct 10, 2026 | bullish | 0.5 | 1 |
| Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock | Eli Lilly (LLY) has been trending on Zacks.com with shares returning +4.2% over the past month, outperforming the S&P 500's +1.3%. The company shows strong fundamentals with expected earnings growth of +40% for the current quarter and +51.3% for the fiscal year. However, the stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock | Eli Lilly (LLY) has been trending on Zacks.com with shares returning +4.2% over the past month, outperforming the S&P 500's +1.3%. The company shows strong fundamentals with expected earnings growth of +40% for the current quarter and +51.3% for the fiscal year. However, the stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| 3 Top-Ranked Healthcare Mutual Funds for a Defensive Portfolio | The article highlights three healthcare mutual funds with Zacks Rank #1 (Strong Buy) ratings as stable investment options. Janus Henderson Global Life Sciences Fund (JNGLX) offers 14.9% five-year annualized returns, Fidelity Select Health Care (FSPHX) provides 13.3% three-year returns with a 0.62% expense ratio, and Fidelity Care Services Portfolio (FSHCX) delivers 2.9% five-year returns. Healthcare sector investments are recommended for their stable demand and dividend-paying pharmaceutical companies. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| 3 Top-Ranked Healthcare Mutual Funds for a Defensive Portfolio | The article highlights three healthcare mutual funds with Zacks Rank #1 (Strong Buy) ratings as stable investment options. Janus Henderson Global Life Sciences Fund (JNGLX) offers 14.9% five-year annualized returns, Fidelity Select Health Care (FSPHX) provides 13.3% three-year returns with a 0.62% expense ratio, and Fidelity Care Services Portfolio (FSHCX) delivers 2.9% five-year returns. Healthcare sector investments are recommended for their stable demand and dividend-paying pharmaceutical companies. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains how the Zacks Earnings ESP (Expected Surprise Prediction) filter helps investors identify stocks likely to beat earnings expectations by comparing the most recent analyst estimates against consensus estimates. Two examples highlighted are United Therapeutics (UTHR) with a +4.99% ESP and Eli Lilly (LLY) with a +1.21% ESP, both positioned to potentially surprise positively in their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains how the Zacks Earnings ESP (Expected Surprise Prediction) filter helps investors identify stocks likely to beat earnings expectations by comparing the most recent analyst estimates against consensus estimates. Two examples highlighted are United Therapeutics (UTHR) with a +4.99% ESP and Eli Lilly (LLY) with a +1.21% ESP, both positioned to potentially surprise positively in their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. | UBS analyst Michael Yee labeled Novo Nordisk a value trap, favoring Eli Lilly's growth prospects in the GLP-1 drug market. However, the article argues that while Eli Lilly currently leads, Novo Nordisk's strong R&D capabilities and 4.7% dividend yield make it a potential long-term turnaround story for patient investors willing to wait 5-10 years for recovery. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.5 | 1 |
| UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. | UBS analyst Michael Yee labeled Novo Nordisk a value trap, favoring Eli Lilly's growth prospects in the GLP-1 drug market. However, the article argues that while Eli Lilly currently leads, Novo Nordisk's strong R&D capabilities and 4.7% dividend yield make it a potential long-term turnaround story for patient investors willing to wait 5-10 years for recovery. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.5 | 1 |
| Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.167 | 1 |
| Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.167 | 1 |
| Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell | Zacks Research Daily features analysis of 16 major stocks on October 8, 2026. Eli Lilly benefits from strong GLP-1 drug demand with positive momentum, Procter & Gamble shows modest growth supported by strong brands and innovation, and Shell demonstrates solid execution and cash generation. Additional coverage includes microcap stocks PrimeEnergy and Aeries Technology, plus analysis of HPE, Jabil, and other companies across various sectors. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell | Zacks Research Daily features analysis of 16 major stocks on October 8, 2026. Eli Lilly benefits from strong GLP-1 drug demand with positive momentum, Procter & Gamble shows modest growth supported by strong brands and innovation, and Shell demonstrates solid execution and cash generation. Additional coverage includes microcap stocks PrimeEnergy and Aeries Technology, plus analysis of HPE, Jabil, and other companies across various sectors. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| SPY is down 0.4% today, on LLY stock price movement - Quiver Quantitative | SPY is down 0.4% today, on LLY stock price movement Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 8, 2026 | neutral | 0 | 0.6 |
| PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer - Yahoo Finance | PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? | Eli Lilly's stock has declined 2.3% in three months despite strong business fundamentals, driven by valuation concerns and competition worries rather than operational deterioration. The company's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, while newly launched oral pill Foundayo is gaining traction with coverage from all major PBMs. Lilly is successfully diversifying beyond GLP-1 with non-cardiometabolic revenues growing 121% in Q2, and the pipeline includes promising candidates like retatrutide. However, headwinds include pricing pressure, rising competition, and slower expected second-half growth. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? | Eli Lilly's stock has declined 2.3% in three months despite strong business fundamentals, driven by valuation concerns and competition worries rather than operational deterioration. The company's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, while newly launched oral pill Foundayo is gaining traction with coverage from all major PBMs. Lilly is successfully diversifying beyond GLP-1 with non-cardiometabolic revenues growing 121% in Q2, and the pipeline includes promising candidates like retatrutide. However, headwinds include pricing pressure, rising competition, and slower expected second-half growth. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Yahoo Finance | LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now | A $1,000 investment in Eli Lilly made in October 2016 would be worth $14,480.69 as of October 8, 2026, representing a 1,348% gain. This significantly outperformed the S&P 500's 262% return over the same period. The pharmaceutical giant's strong performance is driven by its cardiometabolic franchise, particularly GLP-1 drugs Mounjaro and Zepbound, which account for over 55% of revenues. Analysts expect continued upside with new drugs and pipeline progress, though GLP-1 competition and pricing pressures present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now | A $1,000 investment in Eli Lilly made in October 2016 would be worth $14,480.69 as of October 8, 2026, representing a 1,348% gain. This significantly outperformed the S&P 500's 262% return over the same period. The pharmaceutical giant's strong performance is driven by its cardiometabolic franchise, particularly GLP-1 drugs Mounjaro and Zepbound, which account for over 55% of revenues. Analysts expect continued upside with new drugs and pipeline progress, though GLP-1 competition and pricing pressures present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Why You Should Think About Eli Lilly Stock Differently Now - Trefis | Why You Should Think About Eli Lilly Stock Differently Now Trefis | View source ↗ | Trefis | Oct 7, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.